Scarica l'app Stockscreener
1.82
1.68%
0.03
Dopo l'orario di chiusura:
1.81
-0.01
-0.55%
Precedente Chiudi:
$1.79
Aprire:
$1.81
Volume 24 ore:
1.44M
Relative Volume:
0.81
Capitalizzazione di mercato:
$394.69M
Reddito:
$194.75M
Utile/perdita netta:
$-51.26M
Rapporto P/E:
-3.50
EPS:
-0.52
Flusso di cassa netto:
$-23.38M
1 W Prestazione:
-2.15%
1M Prestazione:
+32.85%
6M Prestazione:
+61.06%
1 anno Prestazione:
+84.77%
Intervallo 1D:
$1.75
$1.83
Intervallo di 1 settimana:
$1.75
$1.87
Portata 52W:
$0.80
$2.48
Akebia Therapeutics Inc Stock (AKBA) Company Profile
Nome
Akebia Therapeutics Inc
Settore
Telefono
617-871-2098
Indirizzo
245 FIRST STREET, CAMBRIDGE, MA
Confronta AKBA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| AKBA | 1.82 | 394.69M | 194.75M | -51.26M | -23.38M | -0.52 |
| ZTS | 176.71 | 79.55B | 9.15B | 2.43B | 2.31B | 4.92 |
| HLN | 9.55 | 43.18B | 14.26B | 1.55B | 0 | 0.3327 |
| TAK | 13.33 | 42.26B | 30.27B | 1.93B | 3.45B | 0.444 |
| TEVA | 17.08 | 19.35B | 16.77B | -959.00M | 1.37B | -2.00 |
| VTRS | 13.25 | 15.77B | 15.24B | -646.50M | 1.88B | 1.53 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-03-31 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | Downgrade | Mizuho | Buy → Neutral |
| 2022-03-31 | Downgrade | Needham | Buy → Hold |
| 2022-03-31 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-03-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-01-29 | Downgrade | JP Morgan | Neutral → Underweight |
| 2019-11-14 | Reiterato | Needham | Buy |
| 2019-08-06 | Reiterato | H.C. Wainwright | Buy |
| 2019-07-11 | Reiterato | H.C. Wainwright | Buy |
| 2019-05-02 | Iniziato | JP Morgan | Overweight |
| 2019-03-20 | Iniziato | Citigroup | Neutral |
| 2018-09-07 | Ripresa | Morgan Stanley | Equal-Weight |
| 2018-08-10 | Reiterato | Needham | Buy |
| 2018-06-06 | Reiterato | H.C. Wainwright | Buy |
| 2017-12-19 | Iniziato | Piper Jaffray | Overweight |
| 2017-12-07 | Iniziato | BTIG Research | Buy |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2017-07-10 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-27 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-27 | Reiterato | Needham | Buy |
| 2016-12-27 | Reiterato | H.C. Wainwright | Buy |
| 2016-12-20 | Reiterato | JMP Securities | Mkt Outperform |
| 2016-11-15 | Iniziato | Aegis Capital | Buy |
| 2016-09-29 | Iniziato | Brean Capital | Buy |
| 2016-03-16 | Reiterato | Needham | Buy |
| 2016-01-21 | Iniziato | Credit Suisse | Neutral |
Mostra tutto
Akebia Therapeutics Inc Borsa (AKBA) Ultime notizie
Q3 2024 Earnings: Hold Akebia Therapeutics (NASDAQ:AKBA) - Seeking Alpha
Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease - Yahoo Finance UK
Akebia Therapeutics (NASDAQ:AKBA) Stock Rating Lowered by StockNews.com - Defense World
Akebia Therapeutics to Present at the Jefferies London Healthcare Conference - StockTitan
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q3 2024 Earnings Call Transcript - Insider Monkey
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$5.50 - Yahoo Finance
Earnings call: Akebia reports Q3 results, gears up for Vafseo launch - Investing.com Australia
Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Price Is Right But Growth Is Lacking After Shares Rocket 41% - Simply Wall St
Akebia Therapeutics Inc (AKBA) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ... By GuruFocus - Investing.com Canada
Akebia Therapeutics Inc (AKBA) Q3 2024 Earnings Call Highlights: - GuruFocus.com
Akebia Therapeutics Inc (AKBA) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ... - Yahoo Finance
Akebia Therapeutics: Q3 Earnings Snapshot - CT Insider
Akebia Therapeutics Prepares for Vafseo Launch - TipRanks
Akebia Therapeutics Inc. (AKBA) Quarterly 10-Q Report - Quartzy
Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - citybiz
Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
SEC Form 10-Q filed by Akebia Therapeutics Inc. - Quantisnow
Here's Why You Should Consider Buying Akebia (AKBA) Stock - MSN
Akebia Therapeutics to present at upcoming investor conferences - MSN
Akebia Therapeutics (AKBA) Scheduled to Post Earnings on Thursday - MarketBeat
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Lelezard
Akebia Therapeutics Signs Commercial Supply Contract with Leadin - GuruFocus.com
Akebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights - citybiz
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Short Interest Down 6.0% in October - Defense World
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Short Interest Update - MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) Stock Rating Reaffirmed by HC Wainwright - Defense World
Akebia stock climbs 8% on dialysis provider supply agreement - MSN
High Growth Tech Stocks to Watch in October 2024 - Simply Wall St
Akebia Therapeutics (NASDAQ:AKBA) shareholder returns have been respectable, earning 91% in 1 year - Simply Wall St
Akebia Therapeutics secures dialysis drug contract By Investing.com - Investing.com Australia
Akebia Therapeutics secures dialysis drug contract - Investing.com
Akebia Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits - Quantisnow
Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis - Yahoo Finance
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class ActionAKBA - AsiaOne
Akebia Therapeutics extends supply agreement with STA Pharmaceutical - Investing.com
Akebia Therapeutics extends supply agreement with STA Pharmaceutical By Investing.com - Investing.com UK
Akebia Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement - Quantisnow
Akebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024 - StockTitan
A new trading data show Akebia Therapeutics Inc. (AKBA) is showing positive returns. - SETE News
Akebia Therapeutics Inc.’s latest rating changes from various analysts - Knox Daily
Akebia shares maintain Buy rating on CMS Vafseo payment decision By Investing.com - Investing.com Canada
Marshall Wace LLP Lowers Stake in Akebia Therapeutics, Inc. (NASDAQ:AKBA) - MarketBeat
Akebia shares maintain Buy rating on CMS Vafseo payment decision - Investing.com India
Akebia Therapeutics Inc Azioni (AKBA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.01%
0.30%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):